对未控制的 2 型糖尿病患者进行药剂师干预的评估
以患者为中心的多学科方法对不受控制的 2 型糖尿病患者的药剂师干预和教育的评价
Type 2 diabetes is a chronic disease that can lead to a number of complications if uncontrolled and there is a projected increase of 33% patients living with diabetes over the next 10 years. There can be improvements to modifiable risk factors such as diet and exercise, in addition to medications. Treatment often involves a multidisciplinary approach with a physician, endocrinologist, dietitian, pharmacist and other support health professionals as required. This study will evaluate the effects of the pharmacists (or pharmD interns) intervention, looking at changes to the patients HbA1C, which is a measure of the patients blood glucose control over the previous 3 months as well as the patients understanding and comfort with managing their own diabetes via participant survey.
研究概览
地位
条件
详细说明
Recruitment will begin in July 2022, potential participants can self-refer or another healthcare provider may discuss the study and provide contact information to the study team for all interested potential participants. These potential participants would then be screened for eligibility by the pharmacist or PharmD (Doctor of Pharmacy) Intern. The goal is to enroll 60 participants in the study. All participants must provide consent to participate and will be asked to complete a participant survey.
All participants who consented will then be randomized into a control group which will not receive pharmacist intervention during the study period, or the intervention group which will receive pharmacist/PharmD Intern led intervention which includes a medication review, optimizing medication treatment options and frequent follow up and diabetes education. The control group participants will be offered pharmacist intervention following the study period. All participants will be asked to complete a participant survey at the start and end of the study. All participants will also have standard care from their physicians and other healthcare team members as required which would be standard of practice. All participants would also be asked to repeat their blood work at the end of the study period.
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
Manitoba
-
Portage la Prairie、Manitoba、加拿大、R1N 3V5
- Portage Clinic
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Patients whose primary care physician is within the Portage Clinic
- Adults (age 18 and older) with type 2 diabetes with HbA1C 10 % or above
- Patients whom have not had previous clinical pharmacist directed intervention
- Agree to participate in the study, including frequent follow up, blood glucose home monitoring as directed and repeat lab work
- Willing to consider medication adjustments as deemed appropriate
- Willing to review and sign the Research Participant Information and Informed Consent Form
Exclusion Criteria:
- Patients less than 18 years of age
- Patients with type 1 diabetes, pre-diabetes or gestational diabetes (or whom are pregnant)
- Patients whom have had recent or ongoing clinical pharmacist directed intervention or intensive health care professional monitoring and guidance
- Patients with HbA1C less than 10%
- Patients whom refuse medication adjustments
- Patients with severe renal impairment or receiving dialysis treatments
学习计划
研究是如何设计的?
设计细节
- 主要用途:支持治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
无干预:Control Arm
The participants in this arm will receive standard of care from their physician as they would have been doing previously. This still may involve blood work, referrals to other health providers (except pharmacist) and medication adjustments driven by the pharmacist. |
|
|
有源比较器:Pharmacist Intervention Arm
The participants in this arm will receive standard of care from their physician in addition to pharmacist intervention. The pharmacist or pharmD intern leads the diabetes care for the patient typically, conducting a medication review, recommending medication changes, frequent follow up and requesting blood work and providing referrals to other health care providers as needed,which is standard care |
Pharmacists will review the patients information and medical history as well as drug coverage to discuss preferred treatment options to manage diabetes based on recommendations from Diabetes Canada treatment guidelines; all drugs have been approved and are available on the market; pharmacists will offer frequent follow up and provide basic diabetes education to the patient at each follow up appointment |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Baseline Hemoglobin A1C (HbA1C) at 10 months
大体时间:baseline and through study completion at 10 months approximately
|
Measure of blood glucose control at the lab |
baseline and through study completion at 10 months approximately
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Participant Survey
大体时间:baseline and through study completion at 10 months approximately
|
Evaluating the patients knowledge of diabetes management, comfort with managing their own diabetes care, perception of the pharmacist's role |
baseline and through study completion at 10 months approximately
|
|
Modifiable Risk Factors -Cholesterol Level
大体时间:baseline and through study completion at 10 months approximately
|
evaluating changes in modifiable risk factors such as cholesterol levels reported in mmol/L |
baseline and through study completion at 10 months approximately
|
|
Modifiable Risk Factor - Body Mass Index
大体时间:baseline and through study completion at 10 months approximately
|
evaluating changes in modifiable risk factors such as weight and height which will be combined to report body mass index in kg/m^2 |
baseline and through study completion at 10 months approximately
|
|
Modifiable Risk Factor - Blood Pressure
大体时间:baseline and through study completion at 10 months approximately
|
evaluating changes in modifiable risk factors such as blood pressure reported in mmHg |
baseline and through study completion at 10 months approximately
|
合作者和调查者
出版物和有用的链接
一般刊物
- Schmitt A, Gahr A, Hermanns N, Kulzer B, Huber J, Haak T. The Diabetes Self-Management Questionnaire (DSMQ): development and evaluation of an instrument to assess diabetes self-care activities associated with glycaemic control. Health Qual Life Outcomes. 2013 Aug 13;11:138. doi: 10.1186/1477-7525-11-138.
- APDS Diabetes Knowledge Questionnaire - Baker. (n.d.). Retrieved March 22, 2022, from https://www.baker.edu.au/-/media/documents/impact/ausdiab/questionnaires/ausdiab-diabetes-knowledge-questionnaire-2004.pdf?la=en
- 36-Item Short form survey instrument (SF-36). RAND Corporation. (n.d.). Retrieved March 21, 2022, from https://www.rand.org/health-care/surveys_tools/mos/36-item-short-form/survey-instrument.html
- Jacobson, A. M., & Diabetes Control & Complications Trial Research Group. (1994). The Diabetes Quality of Life Measure. In C. Bradley (Ed.), Handbook of psychology and diabetes: A guide to psychological measurement in diabetes research and practice (pp. 65-87). Harwood Academic Publishers/Gordon.
- Bradley C: The Diabetes Treatment Satisfaction Questionnaire: DTSQ. In Handbook of Psychology and Diabetes: a guide to psychological measurement in diabetes research and practice. Edited by: Bradley C. Chur, Switzerland: Harwood Academic Publishers; 1994:111-132
- Syarifuddin S, Nasution A, Dalimunthe A, Khairunnisa. Impact of Pharmacist Intervention on Improving the Quality of Life of Patients with Type 2 Diabetes Mellitus. Open Access Maced J Med Sci. 2019 Apr 29;7(8):1401-1405. doi: 10.3889/oamjms.2019.140. eCollection 2019 Apr 30.
- Bukhsh A, Nawaz MS, Ahmed HS, Khan TM. A randomized controlled study to evaluate the effect of pharmacist-led educational intervention on glycemic control, self-care activities and disease knowledge among type 2 diabetes patients: A consort compliant study protocol. Medicine (Baltimore). 2018 Mar;97(12):e9847. doi: 10.1097/MD.0000000000009847.
- Abdulrhim S, Awaisu A, Ibrahim MIM, Diab MI, Hussain MAM, Al Raey H, Ismail MT, Sankaralingam S. Impact of pharmacist-involved collaborative care on diabetes management in a primary healthcare setting using real-world data. Int J Clin Pharm. 2022 Feb;44(1):153-162. doi: 10.1007/s11096-021-01327-x. Epub 2021 Oct 12.
- Stading, J., Herrmann, J., Walters, R., Destache, C., Chock, A. (2009). Impact of Pharmacist Intervention on Diabetes Patients in an Ambulatory Setting. Diabetes Spectrum, Volume 22, Number 4, (241-246). https://diabetesjournals.org/spectrum/article/22/4/241/2441/Impact-of-Pharmacist-Intervention-on-Diabetes
- Jennings DL, Ragucci KR, Chumney EC, Wessell AM. Impact of clinical pharmacist intervention on diabetes related quality-of-life in an ambulatory care clinic. Pharm Pract (Granada). 2007 Oct;5(4):169-73. doi: 10.4321/s1886-36552007000400005.
- Butt M, Mhd Ali A, Bakry MM, Mustafa N. Impact of a pharmacist led diabetes mellitus intervention on HbA1c, medication adherence and quality of life: A randomised controlled study. Saudi Pharm J. 2016 Jan;24(1):40-8. doi: 10.1016/j.jsps.2015.02.023. Epub 2015 Mar 6.
- Shane-McWhorter L, McAdam-Marx C, Lenert L, Petersen M, Woolsey S, Coursey JM, Whittaker TC, Hyer C, LaMarche D, Carroll P, Chuy L. Pharmacist-provided diabetes management and education via a telemonitoring program. J Am Pharm Assoc (2003). 2015 Sep-Oct;55(5):516-26. doi: 10.1331/JAPhA.2015.14285.
有用的网址
- <p>Diabetes Canada (2022, March). Diabetes in Manitoba: Backgrounder. Ottawa: Diabetes Canada; 2021.</p>
- <p>Canadian Pharmacists Association, (2022, March). More and more Canadians say pharmacists play essential role in Canada's health care system, 2017.</p>
- <p>The Canadian Diabetes Association. (2018). Diabetes Canada Clinical Practice Guidelines. Resources for People with Diabetes, Diabetes Fact Sheet.</p>
- <p>The Canadian Diabetes Association. (2018). Diabetes Canada Clinical Practice Guidelines. Resources for People with Diabetes, Type 2 Diabetes: The Basics</p>
- <p>The Canadian Diabetes Association. (2018). Diabetes Canada Clinical Practice Guidelines. Resources for People with Diabetes, My Diabetes Care: not just about blood sugars.</p>
- <p>The Canadian Diabetes Association. Resources for People with Diabetes, Self monitoring blood glucose log.</p>
- <p>The Canadian Diabetes Association. (2018). Diabetes Canada Clinical Practice Guidelines. Resources for People with Diabetes, Goal Calendar.</p>
- <p>The Canadian Diabetes Association. (2018). Diabetes Canada Clinical Practice Guidelines. Resources for People with Diabetes, Managing my Diabetes - My Action Plan.</p>
- <p>The Canadian Diabetes Association. Resources for People with Diabetes, Sick Day Management Tool.</p>
- <p>The Canadian Diabetes Association. (2018). Diabetes Canada Clinical Practice Guidelines. Resources for People with Diabetes, Lows and Highs: blood sugar levels</p>
- <p>The Canadian Diabetes Association. (2018). Diabetes Canada Clinical Practice Guidelines. Resources for People with Diabetes, Hypoglycemia: low blood sugar in adults.</p>
- <p>The Canadian Diabetes Association. (2014). Diabetes Canada Clinical Practice Guidelines. Patient resources, Medication sheet: Biguanide</p>
- <p>The Canadian Diabetes Association. (2014). Diabetes Canada Clinical Practice Guidelines. Patient resources, Medication sheet: DPP-4 Inhibitor</p>
- <p>The Canadian Diabetes Association. (2014). Diabetes Canada Clinical Practice Guidelines. Patient resources, Medication sheet: GLP-1 Receptor Agonist</p>
- <p>The Canadian Diabetes Association. (2015). Diabetes Canada Clinical Practice Guidelines. Patient resources, Medication sheet: SGLT2 Inhibitors</p>
- <p>The Canadian Diabetes Association. (2014). Diabetes Canada Clinical Practice Guidelines. Patient resources, Medication sheet: Sulfonylurea insulin secretagogues</p>
- <p>The Canadian Diabetes Association. (2018). Diabetes Canada Clinical Practice Guidelines. Quick Reference Guide.</p>
- <p>The Canadian Diabetes Association. (2017). Tools and Resources, Insulin Prescription</p>
- <p>The Canadian Diabetes Association. (2018). Diabetes Canada Clinical Practice Guidelines. Tools and Resources, Insulin pen start checklist</p>
- <p>The Canadian Diabetes Association. (2018). Appendix 7: Therapeutic Considerations for Renal Impairment. (2018). Canadian Journal of Diabetes, 42</p>
- <p>The Canadian Diabetes Association. (2020). 2020 Chapter Updates: Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update</p>
- <p>Health Canada. (April 2020). Side Effect Reporting Form</p>
- <p>The Canadian Diabetes Association. (2018). Appendix 6: Types of insulin. (2018). Canadian Journal of Diabetes, 42</p>
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.